News

Intellect will transfer all of Intellect’s intellectual property rights and data related to OX1 research and development program, to ViroPharma for $6.5m up-front licensing fee. The agreement has

During the course of the study, groups of mice were fed with specially formulated diets containing 5% freeze-dried blueberry powder, 10% blueberry powder or a control diet containing

During the course of the trial, 18 HIV-positive, treatment-naive patients will be treated with the drug for over 10 days. In addition, eight more patients will be given

The PDP is said to be a zero-dollar deductible Part D plan by the company. First Health Value Plus, built on preferred pharmacy networks, offers lower member co-payments

The clinic has opned a new department to conduct the study. Reveal will test the efficacy of the new drug Anacetrapib to boost HDL levels in patients 50

The EA will assess plant operation, macrolide branded generics and active pharmaceutical ingredients (API) production. The company should abide by regulatory guidelines in terms of surface and ground

The Proteus series of Proton Therapy solutions offer radiotherapy with fewer clinical consequences and is expected to treat 250 to 2,000 patients annually with protons. The solution comprises

At its new site, Diagnovus will develop diagnostic tests and offer information about rare forms of cancer, including pediatric cancers to physicians, payers, patients and families. The new

G-Zero will use the award to continue studies towards ‘Organismal Radioprotection through Pharmacological Quiescence’. Previously in late 2009, the company has also received $0.6m through a phase I